Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® ...

This important study offers insights into the function and connectivity patterns of a relatively unknown afferent input from the endopiriform to the CA1 subfield of the ventral hippocampus, suggesting ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

上海团队牵头完成了我国首例临床级iPSC衍生细胞移植治疗帕金森病。新民晚报记者今日了解到，经过一年的随访，患者运动能力及生活质量较细胞 ...

中国首个诱导多能干细胞（iPSC）衍生细胞疗法治疗帕金森病取得突破性进展。记者今天从上海市东方医院获悉，该院与士泽生物医药（苏州）有限 ...

在大规模生产诱导多能干细胞（iPSC）的过程中，确保其质量和多能性以满足临床需求面临着诸多挑战。iPSC的多能状态极为敏感，且对培养基质有较强的依赖性。为了实现可放大的干细胞生物工艺，必须采用能够实时监测细胞分化、生长状态及活性的标记物。